Bliss GVS Pharma Limited has informed the Exchange regarding Board meeting held on July 29, 2025, has considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2025. A copy of the unaudited standalone and consolidated financial results along with the Limited Review Report of the Auditors.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 19.0 pts more than Nifty Microcap 250 and 19.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bliss GVS Pharma's board approved unaudited standalone and consolidated results for Q1 FY26 (quarter ended June 30, 2025). Standalone revenue from operations rose about 9.7% year-on-year to ₹163.36 crore, with net profit up roughly 8.4% at ₹21.05 crore. On a consolidated basis, revenue grew around 13% to ₹207.47 crore, while net profit more than doubled to ₹44.36 crore (from ₹22.11 crore in Q1 FY25). Consolidated basic EPS jumped to ₹4.08 from ₹1.97. The statutory auditors, Kalyaniwalla & Mistry LLP, issued a clean (unmodified) limited review report on both standalone and consolidated results. The company also noted it has divested a 51% stake in step-down subsidiary Greenlife Bliss Healthcare Ltd for USD 1.3 million, effective April 1, 2025, so that entity has been deconsolidated from this quarter.
A sharp jump in consolidated profit and EPS is the main positive takeaway for shareholders, and the clean auditor review removes near-term accounting concerns. The deconsolidation of Greenlife and a near 4x rise in standalone finance costs are points investors may want to monitor going forward.